These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29884102)

  • 1. Improved Fluorescence Methods for High-Throughput Protein Formulation Screening.
    Wei Y; Larson NR; Angalakurthi SK; Russell Middaugh C
    SLAS Technol; 2018 Dec; 23(6):516-528. PubMed ID: 29884102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of High Throughput Screening Techniques to Predict Stability of Monoclonal Antibody Formulations During Early Stage Development.
    Goldberg DS; Lewus RA; Esfandiary R; Farkas DC; Mody N; Day KJ; Mallik P; Tracka MB; Sealey SK; Samra HS
    J Pharm Sci; 2017 Aug; 106(8):1971-1977. PubMed ID: 28456733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput screening and stability optimization of anti-streptavidin IgG1 and IgG2 formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    J Biomol Screen; 2014 Oct; 19(9):1290-301. PubMed ID: 25023322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants.
    McClure SM; Ahl PL; Blue JT
    Pharm Res; 2018 Mar; 35(4):81. PubMed ID: 29508082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis.
    He F; Woods CE; Trilisky E; Bower KM; Litowski JR; Kerwin BA; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Apr; 100(4):1330-40. PubMed ID: 24081468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies.
    Gibson TJ; Mccarty K; Mcfadyen IJ; Cash E; Dalmonte P; Hinds KD; Dinerman AA; Alvarez JC; Volkin DB
    J Pharm Sci; 2011 Mar; 100(3):1009-21. PubMed ID: 21280052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput assessment of thermal and colloidal stability parameters for monoclonal antibody formulations.
    He F; Woods CE; Becker GW; Narhi LO; Razinkov VI
    J Pharm Sci; 2011 Dec; 100(12):5126-41. PubMed ID: 21789772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL).
    Zhao H; Graf O; Milovic N; Luan X; Bluemel M; Smolny M; Forrer K
    J Pharm Sci; 2010 May; 99(5):2279-94. PubMed ID: 20014026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage.
    Svilenov H; Winter G
    Eur J Pharm Biopharm; 2019 Apr; 137():131-139. PubMed ID: 30818009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: role of conformational and colloidal stability.
    Goldberg DS; Bishop SM; Shah AU; Sathish HA
    J Pharm Sci; 2011 Apr; 100(4):1306-15. PubMed ID: 20960568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Micro-Polyethylene Glycol Precipitation Assay as a Relative Solubility Screening Tool for Monoclonal Antibody Design and Formulation Development.
    Toprani VM; Joshi SB; Kueltzo LA; Schwartz RM; Middaugh CR; Volkin DB
    J Pharm Sci; 2016 Aug; 105(8):2319-27. PubMed ID: 27368120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants.
    Menzen T; Friess W
    J Pharm Sci; 2013 Feb; 102(2):415-28. PubMed ID: 23212746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications of Differential Scanning Fluorometry and Related Technologies in Characterization of Protein-Ligand Interactions.
    Baljinnyam B; Ronzetti M; Yasgar A; Simeonov A
    Methods Mol Biol; 2020; 2089():47-68. PubMed ID: 31773647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Throughput Screening and Analysis of Charge Variants of Monoclonal Antibodies in Multiple Formulations.
    Alekseychyk L; Su C; Becker GW; Treuheit MJ; Razinkov VI
    SLAS Discov; 2017 Sep; 22(8):1044-1052. PubMed ID: 28570837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Nature of High-Throughput Assays in ADC Formulation Screening.
    Mills BJ; Godamudunage MP; Ren S; Laha M
    J Pharm Sci; 2023 Jul; 112(7):1821-1831. PubMed ID: 37037342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody.
    Niedziela-Majka A; Kan E; Weissburg P; Mehra U; Sellers S; Sakowicz R
    J Biomol Screen; 2015 Apr; 20(4):552-9. PubMed ID: 25385011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of formulation variables on protein stability and integrity of a model IgG4 monoclonal antibody and translation to formulation of a model ScFv.
    Gourbatsi E; Povey JF; Smales CM
    Biotechnol Lett; 2018 Jan; 40(1):33-46. PubMed ID: 28939995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies.
    Li Y; Mach H; Blue JT
    J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
    Yang Y; Velayudhan A; Thornhill NF; Farid SS
    Biotechnol Bioeng; 2017 Sep; 114(9):2043-2056. PubMed ID: 28464235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities.
    Whitaker N; Xiong J; Pace SE; Kumar V; Middaugh CR; Joshi SB; Volkin DB
    J Pharm Sci; 2017 Nov; 106(11):3230-3241. PubMed ID: 28668340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.